After the recent study of Ok et al. where EBV+ and CD30+ conferred an inferior outcome for DLBCL treated with R-CHOP, the authors suggest that brentuximab could be used to target CD30 in this patient's subset [26]. This evidence concerns the gene TNFRSF8 and diffuse large B-cell lymphoma.